NEDD4 and cancer: The E3 ubiquitin ligase NEDD4 is a negative regulator of HER3 level and signaling, and NEDD4 expression was inversely correlated with HER3 levels in prostate cancer clinical samples, and its expression was suggested to serve a biomarker for HER3 targeted antibody cancer therapies [20].